Literature DB >> 23233085

Correlation between therapy response assessment using FDG PET/CT and histopathologic tumor regression grade in hepatic metastasis of colorectal carcinoma after neoadjuvant therapy.

Irene A Burger1, Esther I Schwarz, Andrei Samarin, Stefan Breitenstein, Achim Weber, Thomas F Hany.   

Abstract

PURPOSE: To evaluate the correlation between change in FDG uptake before and after chemotherapy in hepatic metastases of colorectal carcinoma (HCRC) and a histopathologic tumor regression grade (TRG).
METHODS: In patients with HCRC, PET/CT data prior to hepatic surgery were retrospectively analyzed under an IRB waiver. The maximum standard uptake value (SUVmax) was measured before and after chemotherapy. The relative change of FDG activity in the identified lesions was calculated (dSUV). Histopathological specimens of resected metastases were graded on a 5-score TRG scale. A TRG of 1-3 was rated as a responding to therapy, whereas TRG 4-5 were regarded as non-responding lesions.
RESULTS: 31 lesions were identified in 23 patients. Mean SUVmax before and after therapy was 6.9 ± 3.7 and 3.5 ± 1.8, respectively. The area under the receiver operator characteristic curve revealed a conclusive correlation between TRG and dSUV (AUC 0.773; 95% confidence interval 0.599-0.946) with a cut off at 41% decrease in FDG activity yielding a sensitivity and specificity of 72 and 75%, respectively.
CONCLUSION: A relative change in FDG activity (dSUV) of more than 41% decrease correlated significantly with histopathological tumor regression and might be a prognostic tool for response to chemotherapy in HCRC.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23233085     DOI: 10.1007/s12149-012-0670-8

Source DB:  PubMed          Journal:  Ann Nucl Med        ISSN: 0914-7187            Impact factor:   2.668


  4 in total

1.  Decreased ERCC1 Expression After Platinum-Based Neoadjuvant Chemotherapy in non-Small Cell Lung Cancer.

Authors:  Eszter Podmaniczky; Katalin Fábián; Judit Pápay; Rita Puskás; Márton Gyulai; József Furák; László Tiszlavicz; György Losonczy; József Tímár; Judit Moldvay
Journal:  Pathol Oncol Res       Date:  2014-09-07       Impact factor: 3.201

2.  18F-FDG PET/CT of Non-Small Cell Lung Carcinoma Under Neoadjuvant Chemotherapy: Background-Based Adaptive-Volume Metrics Outperform TLG and MTV in Predicting Histopathologic Response.

Authors:  Irene A Burger; Ruben Casanova; Seraina Steiger; Lars Husmann; Paul Stolzmann; Martin W Huellner; Alessandra Curioni; Sven Hillinger; C Ross Schmidtlein; Alex Soltermann
Journal:  J Nucl Med       Date:  2016-01-28       Impact factor: 10.057

3.  Early Assessment of Response to Neoadjuvant Chemotherapy with 18F-FDG-PET/CT in Patients with Advanced-Stage Ovarian Cancer.

Authors:  Young Shin Chung; Hyun-Soo Kim; Jung-Yun Lee; Won Jun Kang; Eun Ji Nam; Sunghoon Kim; Sang Wun Kim; Young Tae Kim
Journal:  Cancer Res Treat       Date:  2020-04-28       Impact factor: 4.679

Review 4.  The Value of 18F-FDG-PET-CT Imaging in Treatment Evaluation of Colorectal Liver Metastases: A Systematic Review.

Authors:  Okker D Bijlstra; Maud M E Boreel; Sietse van Mossel; Mark C Burgmans; Ellen H W Kapiteijn; Daniela E Oprea-Lager; Daphne D D Rietbergen; Floris H P van Velden; Alexander L Vahrmeijer; Rutger-Jan Swijnenburg; J Sven D Mieog; Lioe-Fee de Geus-Oei
Journal:  Diagnostics (Basel)       Date:  2022-03-15
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.